Form 4: Director Kathryn Boor Receives Sarepta Therapeutics RSUs

Sarepta Therapeutics director Kathryn Boor was granted 16,875 restricted stock units as part of an equity compensation award.

Summary

• Director Kathryn Boor acquired 16,875 restricted stock units (RSUs) in Sarepta Therapeutics, Inc. (SRPT).
• Each RSU represents a contingent right to receive one share of common stock.
• The grant increases the director's total beneficial ownership to 25,138 shares of common stock.
• The RSUs are subject to a vesting schedule tied to the earlier of the one-year anniversary of the grant or the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a standard equity grant for a board member.

Risks

• Standard market risks associated with holding equity in a biotechnology company.

Future Outlook

The RSUs will vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders occurring at least 50 weeks after the previous year's meeting.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices in the biotechnology sector to ensure director retention and alignment with shareholder interests.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with standard compensation practices for mid-to-large cap biotechnology firms.
• Vesting schedules tied to annual meetings are common practice for board-level equity awards.

Stakeholder Impact

• Minimal impact on shareholders; represents standard director compensation.

Next Steps

• Vesting of the 16,875 RSUs upon the earlier of the one-year anniversary or the next annual meeting.

Key Dates

Keywords

Sarepta Therapeutics, SRPT, Form 4, Insider Trading, Director Compensation, Biotech